(Q38553911)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

1 reference

title

Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

main subject

personalized medicine

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Georg Heinze

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Hiddo J Lambers Heerspink

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Rainer Oberbauer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Andreas Heinzel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Gert Mayer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Bernd Mayer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

1 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

Nephrology Dialysis Transplantation

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

30 Suppl 4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

iv105-112

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Epidemiological Perspectives of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Global variation in renal replacement therapy for end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Perspectives on systems biology applications in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Combined angiotensin inhibition for the treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Avosentan for overt diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

How to improve R&D productivity: the pharmaceutical industry's grand challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Phase III and submission failures: 2007–2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Predictors of congestive heart failure after treatment with an endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Precision medicine for managing diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Applications of CYP450 testing in the clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Genetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV210

21 January 2018

Identifiers

DOI

10.1093/NDT/GFV210

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209732%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference